- 1 Mapping disparities in viral infection rates using highly-multiplexed serology
- 2
- 3 Alejandra Piña<sup>\*1</sup>, Evan A Elko<sup>\*1</sup>, Rachel Caballero<sup>2</sup>, Mary Mulrow<sup>2</sup>, Dan Quan<sup>2,3,4</sup>, Lora
- 4 Nordstrom<sup>2</sup>, John A Altin<sup>5</sup>, Jason T Ladner<sup>1#</sup>
- 5
- 6 Affiliations:
- 7 <sup>1</sup> The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA
- 8 <sup>2</sup> Valleywise Health, Phoenix, AZ, USA
- 9 <sup>3</sup> University of Arizona, College of Medicine, Phoenix, AZ, USA
- 10 <sup>4</sup> Creighton University, School of Medicine, Phoenix, AZ, USA
- <sup>5</sup> The Translational Genomics Research Institute (TGen), Flagstaff, AZ, USA 11
- 12 \* These authors contributed equally
- # Correspondence: Jason.Ladner@nau.edu 13
- 14

#### 15 Abstract

16 Despite advancements in medical interventions, the disease burden caused by viral pathogens remains large and highly diverse. This burden includes the wide range of signs and symptoms 17 18 associated with active viral replication as well as a variety of clinical sequelae of infection. Moreover, there is growing evidence supporting the existence of sex- and ethnicity-based health 19 disparities linked to viral infections and their associated diseases. Despite several well-documented 20 21 disparities in viral infection rates, our current understanding of virus-associated health disparities 22 remains incomplete. This knowledge gap can be attributed, in part, to limitations of the most commonly used viral detection methodologies, which lack the breadth needed to characterize 23 24 exposures across the entire virome. Additionally, virus-related health disparities are dynamic and 25 often differ considerably through space and time. In this study, we utilize PepSeq, an approach for highly-multiplexed serology, to broadly assess an individual's history of viral exposures, and we 26 27 demonstrate the effectiveness of this approach for detecting infection disparities through a pilot study of 400 adults aged 30-60 in Phoenix, AZ. Using a human virome PepSeq library, we 28 observed expected seroprevalence rates for several common viruses and detected both expected 29 30 and previously undocumented differences in inferred rates of infection between our Hispanic 31 White and non-Hispanic White individuals.

32

#### 33 Importance

34 Our understanding of population-level virus infection rates and associated health disparities is

- 35 incomplete. In part, this is because of the high diversity of human-infecting viruses and the
- limited breadth and sensitivity of traditional approaches for detecting infection events. Here, we 36
- 37 demonstrate the potential for modern, highly-multiplexed antibody detection methods to greatly
- increase our understanding of disparities in rates of infection across subpopulations (e.g., 38
- different sexes or ethnic groups). The use of antibodies as biomarkers allows us to detect 39
- 40 evidence of past infections over an extended period of time, and our approach for highly-
- multiplexed serology (PepSeq) allows us to measure antibody responses against 100s of viruses 41
- in an efficient and cost-effective manner. 42
- 43
- 44

### 45 Introduction

46 Despite advancements in the development of medical interventions, the global burden of disease caused by viral pathogens remains substantial and highly diverse. This burden includes a 47 wide range of morbidities associated with active viral replication ranging in severity from fever, 48 49 muscle aches, and rash to encephalitis, immunosuppression, respiratory failure, and congenital birth defects (1-4). Additionally, it includes an array of clinical sequelae of infection (e.g., 50 Guillain-Barre syndrome, Multisystem inflammatory syndrome, Long COVID), many of which 51 52 remain poorly understood (5-7). Viral infections have even been linked to the onset of a number 53 of non-communicable diseases, such as myocarditis (8), diabetes (9), celiac disease (10), obesity (11), multiple sclerosis (12, 13), cancer (14), and Alzheimer's disease (15). 54

Although the health effects caused by viral infections are observed widely in the general 55 population, currently documented national trends highlight several sex- and ethnicity-based health 56 disparities in the prevalence of viral infections and thus, virus-associated disease. For example, in 57 58 the United States (US), seroprevalence of human papillomavirus (HPV) and herpes simplex virus 2 (HSV-2) have been shown to be roughly twice as high among women compared to men (16, 17). 59 In contrast, human immunodeficiency virus 1 (HIV-1) disproportionately affects men in the US, 60 particularly men who have sex with men. In 2021, 69% of new HIV-1 diagnoses in the US were 61 62 among men who have sex with men, despite this group representing only 3.9% of the US population (18, 19). Ethnic disparities have also been documented for HIV-1 in the US. A 2015-63 2019 CDC surveillance report showed the incidence of HIV-1 infection among Hispanics was four 64 65 times higher than that among non-Hispanic Whites. Furthermore, disparities in viral infections can vary in space and time. For example, over a 12 year period the average annual incidence per 66 67 100,000 people of hepatitis A virus (HAV) in a Native American population in Arizona decreased 68 from 289 to 6 due to vaccination efforts (20). Vector-borne viruses provide striking examples of 69 geographical disparities. For example, dengue virus is transmitted by mosquitoes of the genus Aedes that live primarily in tropical regions (21). In 2020 the number of locally transmitted cases 70 71 of dengue virus was 0.025 per 100,000 people in the continental United States, compared to 23.68 72 cases per 100,000 people in Puerto Rico (22).

73 Despite these well documented disparities in viral infection rates, our understanding of 74 virus-associated health disparities remains incomplete. In part, this is because the most commonly 75 used methodologies for detecting viral infections are limited in their breadth, both in terms of the 76 number of viruses they can detect and/or the period of time during which detection is possible. 77 Molecular assays detect viral nucleic acids and therefore lack sensitivity in cases where the infection has already been cleared or if the sampled fluid does not contain the virus (23). In 78 79 contrast, serological assays detect antiviral antibodies that can persist for years after exposure due to the body's long-lived humoral immune response. However, the most commonly used 80 81 serological assays, such as the Enzyme-Linked Immunosorbent Assay (ELISA), only test for one 82 virus (and typically one protein) at a time (24).

Recent advances in serological methods have overcome previous limitations in breadth and
are enabling unprecedented views into the viral exposure histories of individuals (25–28). Using

current approaches for highly-multiplexed serology (e.g., PepSeq (29), PhIP-Seq (30)) it is now 85 86 possible to characterize antibody binding to 100,000s of antigens in a single assay using  $<1 \mu$ L of 87 blood. In this study, we utilize the PepSeq platform to demonstrate the potential of highlymultiplexed serology to broadly characterize differences in seroprevalence across the human 88 89 virome between different demographic groups. Through the characterization of antiviral antibodies 90 in samples collected over ~1 month within a single healthcare system in Phoenix, AZ, we 91 document significant differences in infection rates between the Hispanic White (HW) and non-92 Hispanic White (NHW) populations for several viruses, including some that are rarely included in 93 population-level surveys.

94

## 95 **Results**

96

# 97 Study population

98 Between late May and early June 2020, we collected 400 remnant serum samples from 11 99 Valleywise Health facilities, a large safety net hospital system in Phoenix, AZ. These samples 100 were distributed equally among four subpopulations: 100 HW men, 100 HW women, 100 NHW 101 men and 100 NHW women. To minimize the impact of age-related differences in seropositivity, 102 we limited our focal age range to 30-60 years, and the age distributions were not significantly 103 different (t-test) between genders or ethnicities, with mean age ranging between 45.1 and 46.2 104 (Figure 1A). We also investigated payor source for each sampled individual (Figure 1B), as this 105 can serve as a proxy for socioeconomic status (31). Overall, the vast majority of the individuals 106 included in our study were either covered by a government insurance plan (52.8%; Tricare, 107 Medicare and/or Medicaid) or were uninsured (31.3%; self-pay). Only ~13.1% of the individuals 108 in our study were covered by commercial insurance plans and this percentage did not vary 109 considerably among our subpopulations, though we observed a slightly higher rate of commercial 110 payor for NHW females (20.2%) compared to the other three groups (10-11.2%). However, we 111 did observe substantial differences among our subpopulations in the proportions covered by either 112 government programs or uninsured. The NHW populations were covered in higher proportions by 113 government insurance programs (HW-M: 44.9%, HW-F: 16%, NHW-M: 79.8%, NHW-F: 72.7%), 114 while the HW populations were more likely to be uninsured (HW-M: 39.8%, HW-F: 72%, NHW-115 M: 10.1%, NHW-F: 3%).

116

# 117 PepSeq Analysis

All 400 serum samples were assayed, in duplicate, using our human virome version 1 (HV1) PepSeq library (26), and we obtained an average of 2.2M Illumina sequencing reads per sample, which equates to an average of 9.2 reads per unique HV1 peptide per sample. Four samples were excluded from further analysis due to lower than normal correlation between replicates, which may indicate the occurrence of molecular bottlenecks or contamination of one of the replicates while performing the assay (29). These included two HW males, one NHW male and one NHW female. Therefore, all the analyses presented here include a total sample size of 396.

Based on visual comparisons of experimental samples and buffer-only negative controls 125 126 (Supplemental Figure 1), as well the analysis of a separate group of negative controls that were 127 not considered in the formation of bins or normalization of the data, we chose a set of four different 128 Z score thresholds (10, 15, 20 and 25) for identifying enriched peptides. Higher thresholds are 129 expected to have reduced sensitivity, but increased specificity. To estimate the false positive rate 130 at each of these thresholds, we analyzed all pairwise combinations of 9 buffer-only negative 131 controls (n=36). We observed an average of 5.5, 1.1, 0.28 and 0.17 putatively enriched peptides 132 from these control pseudoreplicate analyses for thresholds of 10, 15, 20 and 25, respectively. In 133 contrast, from the assays of serum samples, we observed an average of 1335, 1071, 926 and 828 134 enriched peptides for thresholds of 10, 15, 20 and 25, respectively. This equates to expected false 135 positive rates of approximately 0.41%, 0.1%, 0.03% and 0.02%, respectively.

To broadly characterize enrichment patterns within our data set, we averaged the number of enriched peptides across all Z score thresholds for each sample. We did not observe significant differences between the average number of enriched peptides by gender (F=1009.92, M=1070.30; t-test p-value=0.135) or ethnicity (HW=1044.37, NHW=1035.55; t-test p-value=0.827) (Figure 2A). We also observed no significant correlation between the number of enriched peptides and age (Figure 2B; Pearson correlation p-value=0.221).

142 The enriched peptides for each Z score threshold were then converted into putative virus 143 species-level serostatus calls using two different sets of potential viruses: one included all 390 144 HV1 target species as viruses to which the study individuals may have been exposed ("Full"), 145 while the other only included 93 viruses ("Focal93"), excluding those that are unlikely to have been encountered by our focal population (Table S1). Overall, in comparing the results from these 146 147 two different sets of potential viruses, we observed strong positive correlations in individual-level estimates of the number of seropositive species (Pearson's correlation coefficients: 0.957 - 0.963; 148 p-values: 1.13e<sup>-214</sup> - 2.50e<sup>-226</sup>) and in species-level estimates of seroprevalence (Pearson's 149 correlation coefficients: 0.983 - 0.997; p-values: 7.35e<sup>-60</sup> - 2.69e<sup>-87</sup>). As expected, we also found 150 151 that most of the seropositive calls using the Full species set were for viruses included in our Focal93 list (76%, 82%, 86%, and 89% for Z score thresholds of 10, 15, 20, and 25, respectively), 152 despite the fact that the Focal93 viruses make up a minority of the Full list of virus species (24%). 153 154 The relatively small number of predicted exposures to viruses outside of our Focal93 subset are 155 likely due to the presence of cross-reactive antibodies and/or true exposure to unusual or 156 uncharacterized viruses. Separately for each set of viruses, we averaged the number of species per 157 sample across all Z score thresholds to broadly characterize patterns within our subpopulations, 158 and we found no significant differences (t-test) in the average number of predicted seropositive 159 species by gender (Focal93: F=29.44, M= 29.92; Full: F=33.58, M=34.11) or by ethnicity (Focal93: HW=29.84, NHW=29.52; Full: HW=34.20, NHW=33.49) (Figure 3A). However, we 160 161 did observe a significant positive correlation between age and the number of predicted seropositive 162 species from both sets of potential viruses (Focal93: Pearson correlation p-value=0.007, Figure 163 3B; Full: Pearson correlation p-value=0.001, not shown).

164 Next, to assess the performance of PepSeq in determining population level seroprevalence across a wide range of virus species, we calculated the estimated seroprevalence for the full cohort 165 166 of 396 samples. This analysis resulted in the estimated seroprevalence for 306 virus species. 167 Among the 20 virus species with the highest seroprevalence, the *Herpesviridae* and *Picornaviridae* 168 families were the most frequently represented (Figure 3C). Seven virus species had an estimated 169 seroprevalence greater than 0.9 (90%; Human gammaherpesvirus 4, Rhinovirus A-C, Human 170 orthopneumovirus, Norwalk virus and Human respirovirus 3) (Figure 3C). For 12 virus species 171 with published seroprevalence studies in the United States, we then compared the PepSeq 172 estimates of seroprevalence with the published estimates based on more traditional singleplex 173 assays (32-41). There was a highly significant correlation between the PepSeq estimated 174 seroprevalence and the estimated seroprevalence found in the literature (p-value=2.72e-5, Pearson 175 R=0.917) (Figure 3D).

176

# 177 Identification of disparities

To identify statistically significant differences in estimated seroprevalence among our subpopulations, we fit a binomial generalized linear model (GLM) with a single dependent variable (seroprevalence) and three independent variables (ethnicity, gender, and age). The results of this analysis using the Full and Focal93 virus sets were remarkably consistent, and all the viruses that exhibited significant differences between subpopulations were present within the Focal93 subset (Table S2). Therefore, we only present the results for the Focal93 set of viruses.

184 In general, across virus species, we observed higher total seropositivity in older individuals, 185 but there was no consistent directional change associated with gender or ethnicity (Supplemental 186 Figure 2). However, no individual viruses exhibited significant correlations between age and 187 seropositivity after correcting for multiple tests, which may be related to the limited range of ages 188 included in this study (30-60 years old). We also found no significant differences in estimated 189 seroprevalence between genders. However, we did observe several viruses with significant 190 correlations between seropositivity and ethnicity, and these patterns were generally consistent 191 across our four Z score thresholds (Figure 4A).

192 In total, ten virus species exhibited ethnicity p-values<0.05 across all four Z score 193 thresholds: cytomegalovirus (CMV, aka human herpesvirus 5), herpes simplex virus 1 (HSV-1) 194 and 2 (HSV-2), human herpesvirus 7 (HHV-7), hepatitis A virus (HAV), salivirus A (SaV-A), 195 parechovirus A (PeV-A), Enterovirus C (EV-C), human adenovirus D (HAdV-D) and human 196 coronavirus OC43 (HCoV-OC43). After Bonferroni correction for multiple tests, seven of these 197 remained significant at  $\geq 1$  Z score threshold and five remained significant across all four Z score 198 thresholds (Figure 4A). Within the HW subpopulation, we observed significantly higher 199 seropositivity for CMV, HSV-1, HAdV-D and HAV across all four Z thresholds and for SaV-A at 200 a Z threshold of 10 (Figure 4A). Within the NHW subpopulation, we observed significantly higher 201 seropositivity for HHV-7 across all thresholds and for PeV-A at Z thresholds of 15 and 20.

For all ten viruses showing significant or nearly significant differences in seroprevalence between ethnicities, we also looked at the relationship between seropositivity and insurance status.

204 Specifically, using a Z score threshold of 15, we compared seroprevalence estimates among three 205 subsets of our study population: insured NHWs (n=185), insured HWs (n=87), and uninsured HWs 206 (n=111). Uninsured NHWs were excluded because of a low sample size (n=13), but generally 207 showed seroprevalence estimates similar to insured NHWs. Our results showed that for most 208 viruses, estimated seroprevalence within insured HWs was intermediate between the NHW insured 209 and HW uninsured subpopulations (Figure 4B). In fact, when considering all ten viruses together, 210 we observed a significant difference between the normalized estimated seroprevalences in the 211 insured HW group compared to the uninsured HW group (absolute values, paired t-test p-212 value=0.013). For all six of the viruses with higher seropositivity among HWs, seropositivity was 213 highest among uninsured individuals, and for half (2/4) of the viruses with lower seropositivity in 214 HWs, seropositivity was lowest in the HW uninsured group. Two viruses, HHV-7 and HCoV-215 OC43, which both had lower seropositivities among HWs, do not follow this trend and have 216 slightly higher seroprevalences in the uninsured HWs compared to the insured HWs.

217 Vaccines are available for two of the virus species with higher seroprevalence in our HW 218 population (HAV and EV-C, which includes poliovirus), and therefore the differences we observed 219 could be due to differences in rates of either natural infection or vaccination. Therefore, we further dissected the antibody responses against these viruses by examining protein- and peptide-level 220 221 reactivity profiles. Notably, all HAV vaccines approved for use in the US are inactivated and it 222 has been shown that antibody responses to natural infection and vaccination can be differentiated 223 by measuring the response to nonstructural proteins, to which a response will only be generated 224 with a natural infection (i.e., when there is virus replication and production of non-structural 225 proteins) (42). Therefore, to examine the role of natural exposure to HAV in the observed 226 difference in seropositivity, we mapped all enriched HAV peptides for each seropositive sample 227 across the HAV proteome. We did not observe a significant difference between HW and NHW 228 cohorts in the proportion of seropositive individuals with  $\geq 1$  enriched peptide from an HAV non-229 structural protein (Fisher's exact test p-value=0.77). In fact, we observed high rates of reactivity 230 against non-structural HAV proteins across both groups (HW=53/71, NHW=17/21) (Figure 5A). 231 These findings indicate that most of the seropositive individuals in our study have likely been 232 naturally infected by HAV and that the observed difference in seroprevalence between HW and 233 NHW is probably not driven by differences in vaccination rate.

234 Next, we sought to determine the role of poliovirus vaccination on the increased 235 seropositivity to EV-C in HWs compared to NHWs. In this case, both inactivated and attenuated (replication competent) vaccines were used in the US prior to 2000, and both are still administered 236 237 in Mexico, which borders Arizona and is the most common source of immigrants in the state (43). 238 Therefore, instead of comparing protein-level patterns of antibody reactivity, we compared 239 antibody reactivity to peptides designed specifically from the three strains of poliovirus. 240 Specifically, we reran our estimates of seropositivity after separating the three polioviruses 241 (UniProt Accessions can be found in Table S3) from the rest of EV-C. In this new analysis, we 242 saw no significant difference in estimated serostatus for poliovirus (p-value = 0.53) with 78 (39%) 243 HW and 83 (42%) NHW positive samples (Figure 5B). However, we did observe a highly

significant difference in seropositivity between HWs and NHWs for "Other EV-C" strains, with
94 (47%) and 14 (7%) seropositive samples, respectively (p-value<0.0001) (Figure 5B). These</li>
results indicate that the observed disparity in EV-C seropositivity between HWs and NHWs is not
driven by differences in natural infection or vaccination with poliovirus but is likely caused by
differences in infection rate with other EV-C viruses.

249 To determine whether there were particular non-polio EV-C viruses that were driving the disparity seen in the "Other EV-C" group, we further analyzed the reactive peptides assigned to 250 251 this group. First, we split the 27 International Committee on Taxonomy of Viruses (ICTV) listed 252 EV-C isolates into six phylogenetic clades (Figure 6A, one clade includes only the polioviruses). Next, we assigned each "Other EV-C" peptide to the most similar EV-C clade (based on shared 253 254 amino acid 7mers) and assigned these peptides scores equivalent to the number of contained 7mers that are unique to that clade. We then calculated relative peptide scores for each EV-C clade by 255 256 summing the scores for 1) all "Other EV-C" peptides in the full HV1 PepSeq library (null 257 distribution) and 2) the subsets of enriched "Other EV-C" peptides observed in the HW and NHW 258 samples that were seropositive for "Other EV-C" (Figure 6B, Supplemental Figure 3). We 259 observed antibody reactivity to peptides assigned to all five "Other EV-C" clades, and the cladespecific relative peptide scores varied substantially between individuals (Supplemental Figure 3). 260 261 These results suggest that a variety of different EV-C viruses may be contributing to the observed disparity in EV-C seropositivity between HWs and NHWs. However, some of these clades (e.g., 262 EV-C 2 and EV-C 3) may be more common than others, based on differences in the relative 263 264 peptide scores between the expected ("Full Library") and observed ("NHW", "HW") distributions 265 (Figure 6B).

# 267 Discussion

266

268 In this study, we used PepSeq, a highly-multiplexed serology platform, to broadly assess virus infection histories and identify differences in seropositivity among various subsets of the 269 270 population served by Valleywise Health in Phoenix, AZ. PepSeq allows for 100,000s of peptide 271 antigens to be simultaneously assayed for antibody reactivity, and thus, it has the potential to 272 facilitate the comprehensive characterization of differences in viral infection rates among subsets 273 of a community. In contrast, the singleplex nature of traditional serological techniques (e.g., 274 ELISA) has required that previous studies focus on a small number of high priority viruses (44, 275 45).

In general, our results were consistent with expectations from previously published studies. 276 277 First, we observed a general trend toward higher seropositivity with increasing age, a pattern that 278 has been reported for a variety of viruses (32-34, 39). In fact, we observed this pattern at two 279 levels: 1) a positive correlation between an individual's age and the number of seropositive virus 280 species called (Figure 3B) and 2) negative age-associated GLM coefficients for most viruses, 281 indicative of higher seroprevalence with increased age (Supplemental Figure 2). Second, we found 282 that overall estimates of seroprevalence for individual viruses were broadly consistent with 283 expectations from molecular and singleplex serological surveys. For example, with a Z score

284 threshold of 15, seven viruses had estimated seropositivities  $\geq 90\%$  (Figure 3C). Among these were 285 five common respiratory viruses, for which the expected seroprevalence is near 100% by adulthood (46): human rhinoviruses A, B and C, human orthopneumovirus (aka respiratory 286 287 syncytial virus) (47) and human respirovirus 3 (aka human parainfluenza virus 3) (48). Also 288 included in this set are human gammaherpesvirus 4 (aka Epstain-Barr virus) and Norwalk virus 289 (aka norovirus), consistent with published serological surveys of adults in the US (33, 38). We also found that relative seroprevalence estimates for closely related viruses were generally 290 291 consistent with documented differences in abundance. For example, while we estimated a 292 seroprevalence for the more common human respirovirus 3 of 91%, the less common 293 "parainfluenza" viruses (human respirovirus 1 and rubulaviruses 2 and 4) were estimated to have 294 seroprevalences of 25-36% (49). Similarly, we estimated the seroprevalence of HSV-1 (85%) to 295 be ~2.2x higher than that of HSV-2 (38%) (Figure 3D), reflecting known differences in prevalence 296 of these related viruses (50). Taken together, these observations provide strong support for the use 297 of our highly-multiplexed serology approach for broadly characterizing virus infection histories.

298 Although we did not observe any statistically significant differences in seropositivity 299 between males and females in our study, we did observe significant differences between HWs and NHWs for seven different viruses, and these differences were largely consistent across different Z 300 301 score thresholds for peptide enrichment (Figure 4A). For five of these viruses (CMV, HSV-1, 302 HAV, SaV-A and HAdV-D), we observed significantly higher seropositivity within our HW 303 subpopulation, while the other two (HHV-7 and PeV-A) showed higher seropositivity in our NHW 304 subpopulation, and several of these significant trends are consistent with published studies, lending 305 additional credibility to our highly-multiplexed approach. For example, we detected higher 306 seropositivity among HWs for both CMV (10-20% higher than among NHWs) and HSV-1 (10-307 30% higher), consistent with the results of previous US population studies that used singleplex 308 antibody assays (32, 50). We also observed significantly higher seropositivity for HAV among 309 HWs, which is consistent with published rates of seropositivity in the US, as well as known 310 differences in seropositivity between the US and Mexico (34, 51–53).

311 We also observed several previously undocumented disparities in infection history between 312 our HW and NHW populations, most of which involved viruses that are rarely targeted in 313 serosurveys. One example is the recently described picornavirus SaV-A, which had ~10% higher 314 seropositivity within our HW subpopulation. Little is known about the seroprevalence of SaV-A 315 in the US, however, it has been documented in wastewater samples from multiple US states, and 316 a study in Arizona found evidence of SaV-A in 15% of wastewater samples (54, 55). Another 317 previously undocumented disparity involves HAdV-D, for which we observed 20-30% higher 318 seropositivity within our HW subpopulation (Figure 4). HAdV-D is a highly diverse species that 319 has been shown to cause severe disease such as epidemic keratoconjunctivitis in 320 immunocompromised individuals. However, little is known about the general health impact of 321 HAdV-D, and therefore, it is difficult to deduce the impact this virus might have on the wellbeing 322 of this population (56). Finally, we estimated significantly higher seroprevalence in our NHW 323 subpopulation for two understudied viruses: PeV-A and HHV-7. PeV-A is a widespread virus that

is associated with respiratory and gastrointestinal symptoms (57–59). However, certain strains of
PeV-A are associated with more severe disease, such as meningitis and sepsis-like illness in infants
(58). HHV-7 is a highly prevalent virus, which is primarily contracted in early childhood, resulting
in life-long latent infections that typically remain asymptomatic. However, HHV-7 has also been
linked with febrile seizures and as a possible cause of encephalitis (60–62). More work is needed
to understand the full impact that these undocumented disparities may have on human health
within these populations.

331 Arizona is home to a large and diverse immigrant population and this has likely contributed to our observed differences in seropositivity among ethnicities. According to estimates from 2018, 332 333 immigrants (i.e., foreign-born individuals) comprised 13% of the population in Arizona, 16% of 334 the state's population were native-born Americans with at least one immigrant parent, and 55% of 335 all immigrants in Arizona were from Mexico, with the next most common countries of origin 336 (Canada, India, Philippines) each accounting for only 4% of the immigrant population (63). 337 Although we did not have access to the immigration status for the individuals included in this 338 study, we were able to examine the payor source associated with each individual's medical visit, 339 and we used a lack of insurance coverage (i.e., "self pay") as a proxy for immigration status. In 340 other words, it was assumed that the uninsured population would contain a higher proportion of 341 immigrants compared to the insured population, and consistent with this assumption, we observed 342 a much higher proportion of uninsured individuals within our HW subpopulation compared to our 343 NHW subpopulation (Figure 1B).

344 By comparing seropositivity estimates between the uninsured and insured HW 345 subpopulations, we were able to demonstrate that, for the majority of viruses that exhibited 346 significant or near significant differences in seropositivity between ethnicities, the insured HW population represented an intermediate level of seropositivity between NHWs and uninsured HWs 347 348 (Figure 4B). This pattern is consistent with the hypothesis that a substantial portion of the 349 differences in seroprevalence between ethnicities can be attributed to differences in seroprevalence 350 between immigrant and non-immigrant populations. Antibody responses to viruses can be long-351 lived. Therefore, one possible explanation is that we are seeing evidence of differences in virus 352 exposure rates, possibly during adolescence, for those who were raised in the US versus those who 353 were raised outside of the US, potentially in less developed, resource-limited countries. Many of 354 the viruses flagged by our analysis are commonly encountered during childhood, and several are 355 known to be more prevalent outside of the US (CMV, HSV-1, and HAV) (64-66). However, other factors, such as differences in the dynamics of virus transmission in immigrant communities within 356 357 the US could also be contributing to the observed patterns.

Virus transmission mechanisms may also play an important role in determining which viruses are most likely to be associated with disparities among ethnic groups. Among the seven viruses with a significant difference in seroprevalence between HWs and NHWs, three are primarily transmitted through intimate contact (CMV, HHV-7, HSV-1), three through the fecaloral route (HAV, PeV-A, SaV-A) and one (HAdV-D) has been associated with a variety of transmission routes, including close personal contact, the fecal-oral route, and respiratory droplets.

Notably absent from this list is respiratory viruses that are primarily spread through airborne transmission, which make up roughly 23% of the focal93 viruses (Table S4). This absence of airborne transmitted viruses is likely due to the wider potential radius for spread from person to person and suggests that viruses that rely on close contact for successful transmission are more likely to be associated with population-level disparities.

369 Among our differentially seropositive species, two (HAV and EV-C) include viruses for 370 which there are widely available vaccines, and for both of these, our highly-multiplexed assay 371 allowed us to assess the relative roles of vaccination and natural infection on the observed 372 differences in seropositivity. For HAV, we were able to differentiate antibody reactivity from 373 vaccination and natural infection by leveraging the ability of PepSeq to simultaneously measure 374 antibody reactivity across multiple HAV protein targets. Specifically, we compared patterns of 375 antibody reactivity between the structural and non-structural proteins of HAV (Figure 5A). For 376 nonstructural proteins to be produced, active replication of viral particles must occur (67). 377 However, all available vaccines in the US contain inactivated viruses, and therefore, vaccination 378 will not elicit antibodies that target nonstructural proteins. Our results show high levels of antibody 379 reactivity against nonstructural HAV proteins in both HW and NHW individuals. This suggests 380 that the higher seroprevalence among HWs is not because of higher vaccination rates in this 381 population.

382 There is also a commonly used vaccine that includes three viruses that belong to the EV-C 383 species — poliovirus 1, 2, and 3 — and both inactivated and live attenuated versions were in use 384 during the lifetimes of our participants. Therefore, to control for differences in antibody responses 385 that may be driven by differences in rates of vaccination, we separated our EV-C peptides into two 386 categories: those that share at least one 7mer with any of the three polioviruses (i.e., those most 387 similar to vaccine antigens) and those that don't. We saw no difference between our ethnicities in 388 reactivity against the peptides most likely to be recognized by vaccine-induced antibodies, but a highly significant difference in reactivity against "Other EV-C" peptides (40% higher 389 390 seropositivity among HWs; Figure 5B). Further analysis showed that the observed antibody 391 reactivity profiles are consistent with past exposures to a wide variety of EV-C viruses 392 (Supplemental Figure 3), but that some phylogenetic clades may be contributing more than others 393 to the observed disparity in EV-C infections between HWs and NHWs (Figure 6B). Notably, while 394 EV-C\_5 peptides are overrepresented in our starting library, they are comparably underrepresented 395 among our enriched peptides, especially in our HW subpopulation (Figure 6B). Interestingly, EV-396 C\_5 has been predominantly isolated from nasal/throat swabs and nasopharyngeal aspirates, 397 suggesting these viruses are likely transmitted via respiratory droplets (68, 69). In contrast, the 398 other EV-C clades have been isolated almost universally from stool samples, indicating that they 399 primarily infect the gastrointestinal tract and are likely to be spread through the fecal-oral 400 transmission pathway (68, 69). This tissue specific tropism aligns with our general hypothesis that 401 the population level virus infection disparities are more commonly driven by viruses that require 402 close contact transmission routes.

### 404 Conclusion

405 Overall, our highly-multiplexed serology assay was successful in broadly characterizing antiviral antibody reactivities and allowed us to infer individual infection histories across the 406 407 virome. The recapitulation of several known differences in seropositivity between two ethnic 408 groups provides confidence in the quality of our analysis and highlights promising future 409 applications for this type of approach. Additionally, our study revealed several previously 410 undocumented disparities in virus seropositivity between HWs and NHWs in our study population. 411 Future studies will be needed to better understand the clinical significance of these differences in 412 infection rates, and to develop medical and social interventions to minimize the impact of these 413 disparities. Our results also demonstrate the potential for highly-multiplexed serology to finely 414 dissect the specificity and breadth of antibody responses, thus enabling an unprecedented view 415 into an individual's history of infection.

416

## 417 Materials and Methods

## 418 <u>Study population and sample collection</u>

419 In total, 400 serum samples were obtained from Valleywise Health in Phoenix, AZ. These 420 samples were collected in late May and early June 2020. They were remnant samples initially 421 collected as a part of the patients' standard of care, and were collected from several different 422 facilities and in a variety of contexts including outpatient encounters (55.5%), inpatient encounters (35%) and emergency department visits (9.5%). Researchers at Northern Arizona University 423 424 (NAU) did not have access to any identifiable patient information. This study was reviewed and approved by the Valleywise Health and NAU Institutional Review Boards (approval number 425 426 1545420).

427 To maximize statistical power to detect differences in seroprevalence, our cohort for this 428 study was equally divided among four sub-populations: HW males (n=100), HW females (n=100), 429 NHW males (n=100) and NHW females (n=100). To minimize the effect of age in detecting 430 differences in seroprevalence, we selected only individuals within an age range of 30-60 years old. 431 Self-reported ethnicity, gender and age were the only characteristics considered for inclusion in 432 this study. However, because Valleywise Health is a safety net hospital, we do not expect our study 433 population to represent a random sampling of the population of Phoenix, AZ. Rather, it is likely to 434 include a higher proportion of individuals with low income and from under-served populations. 435 There is also some potential for bias associated with the use of remnant samples collected from 436 patients actively receiving medical care (compared to a random sample of adults). However, given 437 the wide variety of encounter types represented in our sample, we expect any impact to be minimal.

In total, 83% of the population served by Valleywise Health consists of racial and ethnic minorities, and at the Valleywise Health ambulatory clinics, 59% of patients are Hispanic. The majority of families served by Valleywise Health are at or below 150% of the Federal Poverty Level, and approximately 55% of Valleywise Health patients are enrolled in a government health insurance program for low income people, or have insufficient private insurance or no insurance.

443 For each patient, we also obtained payor source, as this can serve as a useful, though 444 incomplete, indicator of socio-economic status. As the exact payor source is highly variable among 445 individuals, we reduced the complexity of this categorical variable by assigning every individual to one of six general categories: 1) "Commercial", which included all commercial health plans; 2) 446 447 "Medicaid", which included both Arizona Health Care Cost Containment plans and out-of-state Medicaid; 3) "Medicare"; 4) "Dual-SNP", which included any dual special needs plans for 448 individuals who qualify for both Medicaid and Medicare; 5) "Self Pay", for individuals without 449 insurance and 6) "Other", which served as a final catch-all category that included funding through 450 451 charitable organizations like the Ryan White HIV/AIDS Program and other government plans such 452 as Tricare (Table S5).

453

# 454 PepSeq Library Design and Assay

To broadly assess antiviral antibody reactivity, we utilized the PepSeq platform to perform highly-multiplexed peptide-based serology (29). Specifically, we used the human virome version 1 (HV1) library described in (26). In brief, the HV1 library consists of 244,000 unique DNApeptide conjugates (i.e., PepSeq probes). The variable peptide portion of each molecule is 30 amino acids long and the peptides were designed to broadly cover potential linear epitopes present in the proteins of viruses known to infect humans. Libraries of these PepSeq probes are created through a series of bulk, *in vitro* enzymatic reactions (29).

462 Each assay was conducted as described in Ladner et al. (26). Broadly, the PepSeq assay 463 involves the incubation of serum with a diverse pool of PepSeq probes. Immunoglobulin G (IgG) 464 is then precipitated using magnetic protein G beads, non-binding PepSeq probes are washed away, 465 and the relative abundance of each probe is quantified using PCR and high-throughput sequencing of the DNA portion of the molecules (29). Specifically, 5µL of a 1:10 dilution of serum in 466 Superblock T20 (Thermo) was added to 0.1 pmol of the PepSeq library for a total volume of 10 467 uL and was incubated at 20°C overnight. The binding reaction was incubated with pre-washed 468 469 protein G-coated beads (Thermo) for 15 minutes, after which the beads were hand washed 11 times 470 with 1x PBST. After the final wash, beads were resuspended in 30µL of water and heated to 95°C 471 for 5 minutes to elute the bound PepSeq probes. Elutions were amplified and indexed using 472 barcoded DNA oligonucleotides (Table S6). Following PCR, a standard bead cleanup was 473 performed and products were individually quantified (Quant-It, Thermo Fisher), pooled, re-474 quantified (KAPA Library Quantification Kit, Roche) and sequenced on a NextSeq instrument 475 (Illumina). For this study, each sample was assayed in duplicate and  $\geq 1$  buffer-only negative 476 controls were included on each 96-well assay plate. Potential batch effects were controlled through 477 equal representation of each of our four focal subpopulations on each plate, as well as through the 478 inclusion of negative controls from all plates in read count normalization and the generation of the 479 peptide bins.

- 480
- 481
- 482

483 PepSeq Analysis

484 We used PepSIRF v1.5.0 (70, 71) to analyze the high-throughput sequencing data. Demultiplexing and assignment of reads to peptides was done using the *demux* module of PepSIRF 485 486 allowing up to 1 mismatch within each of the index sequences (12 and 8 nt, respectively) and up 487 to 3 mismatches with the expected DNA tag (90 nt). Z scores were calculated using the zscore 488 module of PepSIRF, which implements a method adapted from (72). This process involved the 489 generation of peptide bins, each of which contained  $\geq 300$  peptides with similar expected 490 abundances in our PepSeq library. Expected abundance for each peptide was estimated using 491 buffer-only negative controls. In total, 12 independent buffer-only controls from 7 different assay 492 plates were used to generate the bins for this study. The raw read counts from each of these controls 493 were first normalized to reads per million (RPM) using the column sum normalization method in 494 the *norm* module of PepSIRF. This served to normalize for differences in total sequencing depth 495 between samples. Bins were then generated using the *bin* PepSIRF module. RPM counts for each 496 peptide were then further normalized by subtracting the average RPM count observed within our 497 buffer-only controls. This second normalization step was used to control for any differences in 498 initial relative abundance among peptides contained within the same bin. Each Z score was 499 calculated using peptides contained within the same bin and corresponds to the number of standard 500 deviations away from the mean, with the mean and standard deviation calculated using the 95% 501 highest density interval to exclude any enriched peptides.

The *enrich* module of PepSIRF was used to determine which peptides had been enriched through our assay (i.e., were bound by serum IgG isotype antibodies). This module identifies peptides that meet or exceed minimum Z score thresholds, in both replicates for each sample. Z score thresholds were selected to minimize the number of false positive calls of peptide enrichment (determined through the analysis of negative controls that were not considered in the formation of bins), and multiple Z score thresholds were examined to determine the sensitivity of our results to changes in this threshold.

509 The lists of enriched peptides were converted into lists of putative species-level 510 seropositivities using the *deconv* module of PepSIRF. The goal of this module is to predict the 511 minimum list of viruses to which an individual has likely been infected, while considering shared 512 sequence diversity among different viruses. To accomplish this, the *link* module was first used to 513 generate a linkage map that relates individual peptides to virus species. A link between a peptide 514 and virus indicates that enrichment of the peptide could be explained by exposure to the linked 515 virus species, and these links were made whenever a peptide shared  $\geq 1$  amino acid 7mer with a 516 target protein sequence obtained from a particular virus species. Because of shared sequence 517 diversity, a single peptide can be linked to multiple species, not just the species from which the 518 peptide was designed. Furthermore, the strength of the link between peptides and viruses was 519 quantified with scores that correspond to the number of shared 7mers. Therefore, the maximum 520 link score was 24 and the minimum link score was 1.

521 The HV1 PepSeq library includes peptides derived from 390 virus species, but many of 522 these viruses have only very rarely been associated with human infections (e.g., foot and mouth

disease virus, simian foamy virus) and/or occur in distant and spatially restricted parts of the world
(e.g., Ebola virus, Crimean-Congo hemorrhagic fever virus), and therefore it is very unlikely that
our focal population would have been exposed to these viruses. To determine whether the inclusion
of these viruses was impacting the results of our analysis, we generated two distinct linkage maps.
The first ("Full", Table S1) included all 390 viruses included as targets in the HV1 library design
(26), while the second only included 93 virus species ("Focal93", Table S1), excluding any viruses
to which exposure within the study population was deemed to be very unlikely.

530 The *deconv* module of PepSIRF was then used with each of these linkage maps to identify 531 the most parsimonious set of virus species that can explain each set of enriched peptides. The 532 results, therefore, can be interpreted as potential seropositivities for each sample. The *deconv* 533 module accomplishes this through an iterative process. In each round, species-specific scores are 534 generated by summing the species-level scores from each enriched peptide, and the species with 535 the highest score is selected for inclusion in the output. We set a score threshold of 40; a species 536 must reach or exceed this score in order to be included in the output. Additionally, to account for 537 related species with similar scores, we allowed for ties between species if the lower scoring species 538 had a score  $\geq 80\%$  of the higher scoring species (--score tie threshold 0.8) and if  $\geq 70\%$  of the 539 enriched peptides contributing to these scores were identical between species (--540 score overlap threshold 0.7). In our analysis, we considered an individual to be seropositive for 541 all tied species. Ties accounted for less than 2% of seropositivity calls. A separate *deconv* analysis 542 was run for each Z score threshold.

543

# 544 <u>Identification of disparities</u>

545 To identify significant differences in estimated seropositivity between ethnicities and/or 546 genders, we utilized a generalized linear model (GLM) implemented in Python using statsmodels 547 v3.8.8 (73). Specifically, for each viral species, we fit a binomial GLM with a single dependent 548 variable (seropositivity; 0 or 1 for each individual) and three independent variables [ethnicity 549 (categorical), gender (categorical) and age (continuous)]. We utilized an alpha of 0.05 for 550 determining significance, along with a Bonferroni correction for multiple tests (i.e., number of 551 viruses). To reduce the total number of tests, we only examined viruses with estimated population-552 level seropositivities between 5 and 95%. These thresholds were chosen based on power 553 simulations, which indicated that, with our sample size, it would be unlikely to detect differences 554 in seropositivity <10% as statistically significant.

555

## 556 <u>Subspecies analysis of reactivity profiles</u>

To assign enriched HAV peptides to individual proteins, we first aligned all 360 HAV amino acid sequences from which HV1 peptides were designed using mafft v7.490 (74) with the \*G-INS-i method. Annotations from one of these sequences (Uniprot:Q9DWR1) were then translated into alignment coordinates for the purposes of visualization (Figure 5A) and for assigning peptides to proteins. A peptide was considered structural if  $\geq$ 25 peptide amino acids (83%) were assigned to HAV proteins VP1-4 and/or 2A (blue in Figure 5A). A peptide was

563 considered non-structural if  $\geq$ 25 peptide amino acids were assigned to HAV proteins 2BC and/or 564 3ABCD (green in Figure 5A).

565

566 To determine if the disparity in EV-C seropositivity was driven by differences in vaccination rate, we created a new linkage map where all peptides containing at least one 7mer 567 568 from any of the 2,653 poliovirus sequences (Table S3) used in the creation of the HV1 library were 569 assigned to a new taxonomic category called "poliovirus". All EV-C peptides that did not share a 570 7mer with poliovirus sequences were assigned to an "Other EV-C" category. Next, we reran the 571 *deconv* module using this modified linkage map to estimate seropositivity for these two categories 572 separately. With this analysis, it is possible for an individual sample to be found seropositive for 573 1) just one of these categories, 2) both categories (if there are multiple enriched peptides from each 574 category), or 3) neither of these categories (even for samples previously found to be seropositive 575 for EV-C, if the enriched peptides are split between the new categories). This is a conservative 576 approach for assessing the impact of poliovirus vaccination/infection because it assumes that any 577 antibody recognizing a peptide that shares at least one amino acid 7mer with poliovirus was 578 generated in response to poliovirus infection/vaccination. In reality, these responses could have 579 been stimulated by many different EV-C strains.

580

581 To examine the contribution of different strains of EV-C to our observed "Other EV-C" 582 seropositivities, we assigned each "Other EV-C" peptide to a single subspecies group based on 583 shared amino acid 7mers, with each peptide assigned a score (between 1 and 24) equivalent to the number of contained 7mers that were unique to the assigned group. To improve the sensitivity of 584 585 our analysis (i.e., the number of informative peptides), we focused on clades of related EV-C 586 isolates. As of December 8, 2023, the ICTV website for the Enterovirus genus 587 (https://ictv.global/report/chapter/picornaviridae/picornaviridae/enterovirus) listed NCBI GenBank accession numbers for 27 EV-C isolates, including 6 poliovirus isolates (Table S7). We 588 589 downloaded polyprotein amino acid sequences for each of these and aligned them using mafft 590 v7.490 (74) with default settings. We generated a maximum-likelihood phylogeny from this 591 alignment using raxml-ng v0.5.1b (75) with the LG+FC+I+G8m model, which was selected as 592 optimal using ModelGenerator v0.85 (AIC1) (76). Based on this phylogeny, we divided the EV-C 593 subspecies into six phylogenetic clades, including five composed of non-poliovirus EV-C (EV-594 C\_1-5) (Figure 6). For each enriched "Other EV-C" peptide, we determined the number of amino 595 acid 7mers shared with the ICTV reference sequences from each EV-C clade. We assigned the 596 peptide to the clade with the highest score and normalized the associated score for this peptide by 597 subtracting the next highest clade-specific score (no assignment was made if two clades had 598 identical 7mer scores). To calculate relative reactivity scores against the five non-poliovirus clades 599 ("Relative Peptide Score" in Figure 6B, Supplemental Figure 3), each clade-specific sum of 600 enriched peptide scores was divided by the total sum of scores across all clade-assigned peptides 601 for that sample. For the ethnicity-level composite scores shown in Figure 6B ("HW" and "NHW"), 602 we summed enriched peptide scores across all HW or NHW individuals, respectively, who were

seropositive for our "Other EV-C" category. For these composites, individual peptide scores were
counted once for every sample that exhibited enrichment (i.e., a single peptide could be counted
multiple times if that peptide was recognized by antibodies in multiple samples).

606

# 607 Acknowledgements

We would like to acknowledge Sarah Namdarian for help collecting the clinical samples used in this study. This work was supported by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under Award Number U54MD012388 and the State of Arizona Technology and Research Initiative Fund (TRIF, administered by the Arizona Board of Regents, through Northern Arizona University). The content is solely the responsibility of the authors and does not pageserily represent the official views of the National Institutes of Health

- authors and does not necessarily represent the official views of the National Institutes of Health.
- 614

# 615 Data Availability

616 The raw peptide counts, linkage maps and data related to the figures from this study have been 617 deposited in the Open Science Framework (https://osf.io/gvpzu/), DOI: 618 10.17605/OSF.IO/GVPZU. All custom code is available via GitHub 619 (https://github.com/LadnerLab). Any additional information required to reanalyze the data 620 reported in this paper is available upon request.

621

622



020

627 Figure 1. Demographics of the study population. Remnant serum samples were collected from 628 400 individuals at Valleywise Health in Phoenix, AZ and assayed using the HV1 PepSeq library. 629 Four samples were excluded from the analysis due to poor correlation between replicates. A) The study population ranged in age from 30-60 years old and there was no statistically significant 630 631 difference in the age distributions between genders and ethnicities (t-tests). Individual t-test p-632 values comparing Male/Female and HW/NHW ages are indicated above the respective plots. Each 633 circle represents an individual. The line within each box represents the median, while the lower 634 and upper bounds of each box represent the 1st and 3rd quartiles, respectively. The whiskers extend 635 to points that lie within 1.5 interquartile ranges of the 1st and 3rd quartiles. B) Payor source varied 636 substantially among focal subpopulations. Payor source was consolidated into six general 637 categories (Table S5) and is shown for each subpopulation. Dual-SNP refers to any dual special 638 needs plans for individuals who qualify for both Medicare and Medicaid.



Figure 2. PepSeq identifies similar overall levels of antibody reactivity against viral peptides 640 641 between genders and ethnicities. A) Box plots depicting the average number of enriched PepSeq 642 peptides for each sample across the four Z score thresholds (Z = 10, 15, 20, and 25). Average 643 number of enriched peptides: Female=1009.92, Male=1070.30, HW=1044.37, NHW=1035.55. 644 Individual t-test p-values comparing Male/Female and HW/NHW enriched peptide counts are 645 indicated above the respective plots. Each circle represents an individual. The line within each box 646 represents the median, while the lower and upper bounds of each box represent the 1st and 3rd 647 quartiles, respectively. The whiskers extend to points that lie within 1.5 interquartile ranges of the 648 1st and 3rd quartiles. B) Scatter plot with best-fit line showing average number of enriched 649 peptides by age. Ethnicity is indicated by the color of the points, HW=blue and NHW=orange. 650 Gray diagonal line indicates the best-fit linear regression with the shaded gray areas showing the 651 95% confidence interval. Pearson correlation was used to test for significance (p-value=0.221). 652



653

654 Figure 3. PepSeq-based estimates of seropositivity correlate with age and independent 655 estimates from singleplex assays. A) Box plots depicting the number of virus species selected as 656 seropositive by the PepSIRF *deconv* algorithm for each sample (Focal93 linkage map), divided according to gender (left) and ethnicity (right). Average number of putatively seropositive virus 657 species: Female=29.44, Male=29.92, HW=29.84, NHW=29.52. T-tests comparing Male/Female 658 659 and HW/NHW were non-significant (p-values indicated above the respective plots). Each circle 660 represents an individual. The line within each box represents the median, while the lower and upper bounds of each box represent the 1st and 3rd quartiles, respectively. The whiskers extend to 661 points that lie within 1.5 interguartile ranges of the 1st and 3rd quartiles. B) Scatter plot with best-662 fit line showing average number of predicted seropositive virus species by age. Ethnicity is 663 indicated by the color of the points, HW=blue and NHW=orange. Pearson correlation was used to 664 665 test for significance (p-value = 0.007). Gray diagonal line indicates the best-fit linear regression with the shaded gray areas showing the 95% confidence interval. C) Estimated seroprevalence for 666 667 the 20 most prevalent virus species across the entire patient cohort. Bar colors indicate the viral family. D) PepSeq estimated seroprevalence across the full dataset compared to published 668 669 seroprevalence values from studies in the United States (Table S8). Different estimates for the same virus are connected by a vertical line. The gray diagonal line indicates the best-fit linear 670 regression with the shaded gray areas showing the 95% confidence interval. Pearson's R value and 671 672 p-value shown in the top left. Abbreviations: RSV=respiratory syncytial virus, EBV=Epstein-Barr 673 virus. HHV=Human herpesvirus HSV=herpes simplex virus, CMV=cytomegalovirus, 674 HAV=hepatitis A virus, HIV=human immunodeficiency virus, HCV=hepatitis C virus.



676 Figure 4. Significant differences in seroprevalence by ethnicity and payor status. A) Line plot 677 depicting ten species with a significant difference (p-value<0.05) in seropositivity between HW and NHW calculated by fitting a generalized linear model at each Z score threshold before 678 679 (outlined points) and after (filled points) Bonferroni correction for multiple tests. Negative 680 differences indicate higher seroprevalence in NHWs and positive differences indicate higher 681 seroprevalence in HWs. B) Line plot depicting normalized seroprevalence for the same ten viruses 682 shown in (A), with values calculated separately for insured and uninsured individuals. Seroprevalence is being shown for a Z score threshold of 15 and was normalized against the value 683 684 for insured NHWs. Asterisk indicates the significant increase of the absolute value of the normalized seroprevalence for uninsured HWs compared to insured HWs across all 10 viruses 685 686 (paired t-test p-value=0.013). Abbreviations: CMV=cytomegalovirus, HSV=herpes simplex virus, 687 HHV=human herpesvirus, HAV=hepatitis A virus, SaV-A = salivirus A, PeV-A=parechovirus A, 688 EV-C=Enterovirus C, HAdV-D=human adenovirus D, HCoV-OC43=human coronavirus OC43. 689



690

691 Figure 5. Ethnicity-based disparities in viral infection rates are not driven by vaccination 692 against hepatitis A virus (HAV) or poliovirus. A) Enriched peptides and public epitopes 693 identified in both structural and non-structural HAV proteins. Heatmap of enriched peptides across the HAV proteome for all samples seropositive for HAV with a Z score threshold of 15. Samples 694 695 are broken up by ethnicity on the y-axis and position within the HAV polyprotein is shown on the x-axis (amino acid residues, alignment coordinates). The three most commonly reactive epitopes 696 697 within these samples are highlighted with gray vertical markings. The positions of individual viral 698 proteins are indicated across the top; blue=structural (vaccination or infection) and green=non-699 structural (infection only). B) Bar plot showing the number of seropositive HW (total n=198) and 700 NHW (total n=198) individuals. Seropositivity was calculated using the original linkage map 701 (Focal93) with poliovirus peptides assigned to the Enterovirus C (EV-C) virus species ("All EV-702 C"), or with a modified linkage map where peptides sharing >1 7mer with polioviruses were 703 removed from the EV-C species and treated as their own category ("Poliovirus" and "Other EV-704 C"). P-values for binomial GLM comparing the impact of ethnicity (HW, NHW) on seropositivity 705 are indicated in gray above each viral category. 706



707

708 Figure 6. Antibody reactivity against clade-specific EV-C peptides. A) Maximum-likelihood phylogenetic tree of all 27 ICTV listed EV-C isolates based on an amino acid alignment of the full 709 polyprotein. Branch lengths indicate relative levels of amino acid divergence with the scale bar 710 711 indicating the equivalent of 0.03 changes per site. Black circles indicate nodes with bootstrap support >80. Six phylogenetic clades are identified by the different colors. Genbank accession 712 713 numbers for each sequence can be found in Table S7. B) Bar plot showing clade-specific relative peptide scores for all "Other EV-C" peptides present in the HV1 PepSeq library (Full Library, null 714 715 distribution) compared to the subset of enriched peptides for all HW and NHW individuals predicted to be seropositive against "Other EV-C" (Figure 5B). Each color represents one of the 716 717 "Other EV-C" phylogenetic clades shown in (A).

719720 **References** 

- 1. Tyler KL. 2018. Acute Viral Encephalitis. N Engl J Med 379:557–566.
- 722 2. Naniche D, Oldstone MB. 2000. Generalized immunosuppression: how viruses undermine
  723 the immune response. Cell Mol Life Sci 57:1399–1407.
- Pereira L. 2018. Congenital Viral Infection: Traversing the Uterine-Placental Interface.
   Annu Rev Virol 5:273–299.
- 4. Lu S, Huang X, Liu R, Lan Y, Lei Y, Zeng F, Tang X, He H. 2022. Comparison of COVID19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. Front Med
  9:829771.
- 5. Shahrizaila N, Lehmann HC, Kuwabara S. 2021. Guillain-Barré syndrome. Lancet
  397:1214–1228.
- 731 Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger 6. 732 JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi P, 733 Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, 734 Alharash H, Doymaz S, Clouser KN, Giuliano JS Jr, Gupta A, Parker RM, Maddux AB, 735 Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, 736 Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs CV, Marohn KL, 737 Halasa NB, Patel MM, Randolph AG, Overcoming COVID-19 Investigators, CDC COVID-738 19 Response Team. 2020. Multisystem Inflammatory Syndrome in U.S. Children and 739 Adolescents. N Engl J Med 383:334-346.
- Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser
   K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S,
   Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T,
   Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin
   S, Spector T, Steves CJ. 2021. Attributes and predictors of long COVID. Nat Med 27:626–
   631.
- Tobin NH, Campbell AJP, Zerr DM, Melvin AJ. 2011. Chapter 95 Life-Threatening Viral Diseases and Their Treatment, p. 1324–1335. *In* Fuhrman, BP, Zimmerman, JJ (eds.),
   Pediatric Critical Care (Fourth Edition). Mosby, Saint Louis.
- Filippi CM, von Herrath MG. 2008. Viral trigger for type 1 diabetes: pros and cons.
  Diabetes 57:2863–2871.
- 10. Brown JJ, Jabri B, Dermody TS. 2018. A viral trigger for celiac disease. PLoS Pathog
  14:e1007181.
- Mitra AK, Clarke K. 2010. Viral obesity: fact or fiction? Obesity Reviews
  https://doi.org/10.1111/j.1467-789x.2009.00677.x.

- Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung H-P, Maniar T, Croze E, Aftab BT,
  Giovannoni G, Joshi MA. 2020. Epstein-Barr Virus in Multiple Sclerosis: Theory and
  Emerging Immunotherapies. Trends Mol Med 26:296–310.
- Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW,
  Scher AI, Munger KL, Ascherio A. 2022. Longitudinal analysis reveals high prevalence of
  Epstein-Barr virus associated with multiple sclerosis. Science 375:296–301.
- 14. Sarid R, Gao S-J. 2011. Viruses and human cancer: From detection to causality. Cancer
   Letters https://doi.org/10.1016/j.canlet.2010.09.011.
- 763 15. Devanand DP. 2018. Viral Hypothesis and Antiviral Treatment in Alzheimer's Disease.
  764 Curr Neurol Neurosci Rep 18:55.
- 16. Liu G, Markowitz LE, Hariri S, Panicker G, Unger ER. 2015. Seroprevalence of 9 Human
  Papillomavirus Types in the United States, 2005–2006. J Infect Dis 213:191–198.
- 767 17. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM,
  768 Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in
  769 the United States. JAMA 296:964–973.
- 18. CDC. 2021. HIV and Gay and Bisexual Men.
  https://www.cdc.gov/hiv/group/msm/index.html. Retrieved 15 August 2022.
- Purcell DW, Johnson CH, Lansky A, Prejean J, Stein R, Denning P, Gau Z, Weinstock H,
  Su J, Crepaz N. 2012. Estimating the population size of men who have sex with men in the
  United States to obtain HIV and syphilis rates. Open AIDS J 6:98–107.
- 20. Erhart LM, Ernst KC. 2012. The changing epidemiology of hepatitis A in Arizona following intensive immunization programs (1988-2007). Vaccine 30:6103–6110.
- World Health Organization. 2009. Dengue: Guidelines for Diagnosis, Treatment,
   Prevention and Control. World Health Organization.
- 22. 2022. Statistics and maps 2020. https://www.cdc.gov/dengue/statistics-maps/2020.html.
   Retrieved 23 August 2022.
- 781 23. Hans R, Marwaha N. 2014. Nucleic acid testing-benefits and constraints. Asian J Transfus
  782 Sci 8:2–3.
- 24. Lequin RM. 2005. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay
  (ELISA). Clin Chem 51:2415–2418.
- Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung'u T, Ruxrungtham K, Sanchez J, Brander
  C, Chung RT, O'Connor KC, Walker B, Larman HB, Elledge SJ. 2015. Viral immunology.
  Comprehensive serological profiling of human populations using a synthetic human virome.
  Science 348:aaa0698.

- 26. Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D'ambrozio J,
  Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M,
  Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA.
  2021. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies crossreactivity with endemic human coronaviruses. Cell Rep Med 2:100189.
- 27. Elko EA, Nelson GA, Mead HL, Kelley EJ, Carvalho ST, Sarbo NG, Harms CE, Le Verche
  V, Cardoso AA, Ely JL, Boyle AS, Piña A, Henson SN, Rahee F, Keim PS, Celona KR, Yi
  J, Settles EW, Bota DA, Yu GC, Morris SR, Zaia JA, Ladner JT, Altin JA. 2022. COVID19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved
  with endemic coronavirus spike proteins. Cell Rep 40:111022.
- Kelley EJ, Henson SN, Rahee F, Boyle AS, Engelbrektson AL, Nelson GA, Mead HL,
  Anderson NL, Razavi M, Yip R, Ladner JT, Scriba TJ, Altin JA. 2023. Virome-wide
  detection of natural infection events and the associated antibody dynamics using
  longitudinal highly-multiplexed serology. Nat Commun 14:1783.
- 803 29. Henson SN, Elko EA, Swiderski PM, Liang Y, Engelbrektson AL, Piña A, Boyle AS, Fink
  804 Z, Facista SJ, Martinez V, Rahee F, Brown A, Kelley EJ, Nelson GA, Raspet I, Mead HL,
  805 Altin JA, Ladner JT. 2023. PepSeq: a fully in vitro platform for highly multiplexed serology
  806 using customizable DNA-barcoded peptide libraries. Nat Protoc 18:396–423.
- 30. Mohan D, Wansley DL, Sie BM, Noon MS, Baer AN, Laserson U, Larman HB. 2018.
  PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes. Nat Protoc 13:1958–1978.
- 810 31. Patricia O'Campo JB. 2004. Eliminating Health Disparities: Measurement and Data Needs.
  811 National Academies Press.
- Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. 2006.
  Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43:1143–1151.
- 815 33. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. 2013. Age816 specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the
  817 United States and factors affecting its acquisition. J Infect Dis 208:1286–1293.
- 818 34. Klevens RM, Kruszon-Moran D, Wasley A, Gallagher K, McQuillan GM, Kuhnert W,
  819 Teshale EH, Drobeniuc J, Bell BP. 2011. Seroprevalence of hepatitis A virus antibodies in
  820 the U.S.: results from the National Health and Nutrition Examination Survey. Public Health
  821 Rep 126:522–532.
- 35. McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kington RS. 2004.
  Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United
  States: data from NHANES III, 1988-1994. Am J Public Health 94:1952–1958.
- 36. Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, Takahashi M, Baba K.
  1989. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J

- 827 Clin Microbiol 27:651–653.
- St Louis ME, Rauch KJ, Petersen LR, Anderson JE, Schable CA, Dondero TJ. 1990.
  Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the
  United States. The Sentinel Hospital Surveillance Group. N Engl J Med 323:213–218.
- 831 38. Kirby AE, Kienast Y, Zhu W, Barton J, Anderson E, Sizemore M, Vinje J, Moe CL. 2020.
  832 Norovirus Seroprevalence among Adults in the United States: Analysis of NHANES Serum
  833 Specimens from 1999-2000 and 2003-2004. Viruses 12.
- 834 39. Cangin C, Focht B, Harris R, Strunk JA. 2019. Hepatitis E seroprevalence in the United
  835 States: Results for immunoglobulins IGG and IGM. J Med Virol 91:124–131.
- 40. Cahill ME, Yao Y, Nock D, Armstrong PM, Andreadis TG, Diuk-Wasser MA,
  Montgomery RR. 2017. West Nile Virus Seroprevalence, Connecticut, USA, 2000-2014.
  Emerg Infect Dis 23:708–710.
- 839 41. Schweitzer BK, Kramer WL, Sambol AR, Meza JL, Hinrichs SH, Iwen PC. 2006.
  840 Geographic factors contributing to a high seroprevalence of West Nile virus-specific 841 antibodies in humans following an epidemic. Clin Vaccine Immunol 13:314–318.
- 42. Ye C, Luo J, Wang X, Xi J, Pan Y, Chen J, Yang X, Li G, Sun Q, Yang J. 2017.
  Development of a peptide ELISA to discriminate vaccine-induced immunity from natural infection of hepatitis A virus in a phase IV study. Eur J Clin Microbiol Infect Dis 36:2165– 2170.
- Alfaro-Murillo JA, Ávila-Agüero ML, Fitzpatrick MC, Crystal CJ, Falleiros-Arlant L-H,
  Galvani AP. 2020. The case for replacing live oral polio vaccine with inactivated vaccine in
  the Americas. Lancet 395:1163–1166.
- 44. Kang X, Li Y, Fan L, Lin F, Wei J, Zhu X, Hu Y, Li J, Chang G, Zhu Q, Liu H, Yang Y.
  2012. Development of an ELISA-array for simultaneous detection of five encephalitis
  viruses. Virol J 9:56.
- 45. Fukushi S. 2020. Competitive ELISA for the Detection of Serum Antibodies Specific for
  Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Methods Mol Biol
  2203:55–65.
- 855 46. Boncristiani HF, Criado MF, Arruda E. 2009. Respiratory Viruses, p. 500–518. *In*856 Encyclopedia of Microbiology. Elsevier.
- 47. Dunn SR, Ryder AB, Tollefson SJ, Xu M, Saville BR, Williams JV. 2013.
  Seroepidemiologies of human metapneumovirus and respiratory syncytial virus in young
  children, determined with a new recombinant fusion protein enzyme-linked immunosorbent
  assay. Clin Vaccine Immunol 20:1654–1656.
- 48. Parrott RH, Vargosko AJ, Kimhw, Bell JA, Chanock RM. 1962. Acute respiratory diseases
  of viral etiology. III. parainfluenza. Myxoviruses. Am J Public Health Nations Health

- 863 52:907–917.
- 49. DeGroote NP, Haynes AK, Taylor C, Killerby ME, Dahl RM, Mustaquim D, Gerber SI,
  Watson JT. 2020. Human parainfluenza virus circulation, United States, 2011–2019.
  Journal of Clinical Virology https://doi.org/10.1016/j.jcv.2020.104261.
- Mc Quillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. 2016. Prevalence of Herpes
  Simplex Virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016.
- 869 51. Rubicz R, Leach CT, Kraig E, Dhurandhar NV, Grubbs B, Blangero J, Yolken R, Göring
  870 HH. 2011. Seroprevalence of 13 common pathogens in a rapidly growing U.S. minority
  871 population: Mexican Americans from San Antonio, TX. BMC Res Notes 4:433.
- 52. Ernst KC, Erhart LM. 2014. The role of ethnicity and travel on Hepatitis A vaccination
  coverage and disease incidence in Arizona at the United States-Mexico Border. Hum
  Vaccin Immunother 10:1396–1403.
- 53. Lazcano-Ponce E, Conde-Gonzalez C, Rojas R, DeAntonio R, Romano-Mazzotti L,
  Cervantes Y, Ortega-Barria E. 2013. Seroprevalence of hepatitis A virus in a cross-sectional
  study in Mexico: Implications for hepatitis A vaccination. Hum Vaccin Immunother 9:375.
- 54. Li L, Victoria J, Kapoor A, Blinkova O, Wang C, Babrzadeh F, Mason CJ, Pandey P, Triki
  H, Bahri O, Oderinde BS, Baba MM, Bukbuk DN, Besser JM, Bartkus JM, Delwart EL.
  2009. A novel picornavirus associated with gastroenteritis. J Virol 83:12002–12006.
- 55. Kitajima M, Iker BC, Rachmadi AT, Haramoto E, Gerba CP. 2014. Quantification and
  genetic analysis of salivirus/klassevirus in wastewater in Arizona, USA. Food Environ Virol
  6:213–216.
- 56. Pauly M, Hoppe E, Mugisha L, Petrzelkova K, Akoua-Koffi C, Couacy-Hymann E, Anoh
  AE, Mossoun A, Schubert G, Wiersma L, Pascale S, Muyembe J-J, Karhemere S, Weiss S,
  Leendertz SA, Calvignac-Spencer S, Leendertz FH, Ehlers B. 2014. High prevalence and
  diversity of species D adenoviruses (HAdV-D) in human populations of four Sub-Saharan
  countries. Virol J 11:25.
- 57. Karelehto E, Brouwer L, Benschop K, Kok J, Basile K, McMullan B, Rawlinson W, Druce
  J, Nicholson S, Selvarangan R, Harrison C, Lankachandra K, van Eijk H, Koen G, de Jong
  M, Pajkrt D, Wolthers KC. 2019. Seroepidemiology of Parechovirus A3 Neutralizing
  Antibodies, Australia, the Netherlands, and United States. Emerg Infect Dis 25:148–152.
- Sridhar A, Karelehto E, Brouwer L, Pajkrt D, Wolthers KC. 2019. Parechovirus A
  Pathogenesis and the Enigma of Genotype A-3. Viruses 11.
- S9. Zaki SR, Keating MK. 2018. 13 Viral Diseases, p. 244–288. *In* Zander, DS, Farver, CF
  (eds.), Pulmonary Pathology (Second Edition). Elsevier, Philadelphia.
- 897 60. Oliver S, James SH. 2017. Herpesviruses, p. 621–627. *In* International Encyclopedia of
  898 Public Health. Elsevier.

- 61. Epstein LG, Shinnar S, Hesdorffer DC, Nordli DR, Hamidullah A, Benn EKT, Pellock JM,
  Frank LM, Lewis DV, Moshe SL, Shinnar RC, Sun S, FEBSTAT study team. 2012. Human
  herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia 53:1481–
  1488.
- 62. Li Y, Qu T, Li D, Jing J, Deng Q, Wan X. 2022. Human herpesvirus 7 encephalitis in an
  immunocompetent adult and a literature review. Virol J 19:200.
- 905 63. 2020. Immigrants in Arizona. American Immigration Council.
- Wald A, Corey L. Persistence in the population: epidemiology, transmission, p. . *In* Arvin,
  A, Campadelli-Fiume, G, Mocarski, E, Moore, PS, Roizman, B, Whitley, R, Yamanishi, K
  (eds.), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge
  University Press, Cambridge.
- 65. Cao G, Jing W, Liu J, Liu M. 2021. The global trends and regional differences in incidence
  and mortality of hepatitis A from 1990 to 2019 and implications for its prevention. Hepatol
  Int 15:1068–1082.
- 86. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. 2019.
  81. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and
  81. meta-analysis. Rev Med Virol 29:e2034.
- 816 67. Robertson BH, Jia XY, Tian H, Margolis HS, Summers DF, Ehrenfeld E. 1992. Serological approaches to distinguish immune response to hepatitis A vaccine and natural infection.
  818 Vaccine 10 Suppl 1:S106–9.
- 68. Tokarz R, Haq S, Sameroff S, Howie SRC, Lipkin WI. 2013. Genomic analysis of
  coxsackieviruses A1, A19, A22, enteroviruses 113 and 104: viruses representing two clades
  with distinct tropism within enterovirus C. J Gen Virol 94:1995–2004.
- 922 69. Brouwer L, Benschop KSM, Nguyen D, Kamau E, Pajkrt D, Simmonds P, Wolthers KC.
  923 2020. Recombination Analysis of Non-Poliovirus Members of the Enterovirus C Species;
  924 Restriction of Recombination Events to Members of the Same 3DPol Cluster. Viruses 12.
- 925 70. Fink ZW, Martinez V, Altin J, Ladner JT. 2020. PepSIRF: a flexible and comprehensive
  926 tool for the analysis of data from highly-multiplexed DNA-barcoded peptide assays. arXiv
  927 preprint arXiv:2007 05050.
- 928 71. Brown AM, Bolyen E, Raspet I, Altin JA, Ladner JT. 2022. PepSIRF + QIIME 2: software
  929 tools for automated, reproducible analysis of highly-multiplexed serology data
  930 https://doi.org/10.48550/ARXIV.2207.11509.
- 931 72. Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, Siljander H, Rewers M, Choy DF,
  932 Wilson MS, Larman HB, Nelson AN, Griffin DE, de Swart RL, Elledge SJ. 2019. Measles
  933 virus infection diminishes preexisting antibodies that offer protection from other pathogens.
  934 Science 366:599–606.

- 935 73. Seabold S, Perktold J. 2010. Statsmodels: Econometric and statistical modeling with
  936 pythonProceedings of the 9th Python in Science Conference. SciPy.
- 74. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7:
  improvements in performance and usability. Mol Biol Evol 30:772–780.
- 75. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. 2019. RAxML-NG: a fast,
  scalable and user-friendly tool for maximum likelihood phylogenetic inference.
  Bioinformatics 35:4453–4455.
- 76. Keane TM, Creevey CJ, Pentony MM, Naughton TJ, McInerney JO. 2006. Assessment of
  methods for amino acid matrix selection and their use on empirical data shows that ad hoc
  assumptions for choice of matrix are not justified. BMC Evol Biol 6:29.